Ryan Ungaro is a Gastroenterology physician. ClinicalTrials.gov lists 2 registered studies matched to this name.
Overview
Scholarship
indexed output and impact (OpenAlex)Research metrics aren't shown for this record. Either we found no confident publication match for this name, or more than one physician shares the matched author record. We'd rather show nothing than someone else's numbers. Why? →
Clinical & industry
trials, payments and federal fundingContact
The practice address and phone this provider lists in the federal NPPES (CMS) registry.
Practice address
17 E 102nd St
New York, NY 100295204
Telephone
212-241-8100Registry record last updated 22 Feb 2019.
Clinical trials
- Combination CurQD and Vedolizumab in Ulcerative Colitis
Sponsor: Ryan C Ungaro
- Behavioral Therapy for Crohn's Disease
Sponsor: Icahn School of Medicine at Mount Sinai
Registered studies on ClinicalTrials.gov where the overall official or a site investigator name-matches this physician, confirmed against known institution/geography. Latest few shown; the full list is part of the full profile.
Industry payments
13 companies reported payments to CMS in program years 2021 onward. These are public disclosures, not judgments. The latest:
- ABBVIE INC.Program year202519 payments$25,935openpaymentsdata.cms.gov ↗
- Janssen Global Services, LLCProgram year20255 payments
- PFIZER INC.Program year20253 payments
Payment records matched to this physician's NPI in CMS Open Payments, program years 2021 onward.
Medicare prescribing footprint (2024)
The drugs this prescriber writes for Medicare patients, grouped by drug class and therapeutic area. Every percentage is a share of their total prescribing, so you can see what they prescribe most. These are proportions, not patient counts or dollar amounts. No condition is inferred: the claims record what was prescribed, never why.
Cancer & immunology
62.2%Interleukin-12 Antagonist34.4%Stelara100%Part D<11 patientsJAK inhibitor15.6%Xeljanz100%Part D<11 patients+ 1 more class in this area
Metabolism & gastrointestinal
37.8%Aminosalicylate37.8%Mesalamine100%Part D<11 patients
Drug classes come from the WHO ATC and U.S. National Library of Medicine (RxClass) classifications; prescribing counts come from the CMS Medicare Part D Prescribers file. Each drug is counted once, under its primary class. Medicare fee-for-service only, so no Medicare Advantage, commercial, or pediatric prescribing is included. CMS publishes this data about 17 months after the fact.
NIH funding
2 NIH research awards on record, funded 2019–2024 per NIH RePORTER. The latest:
- Blood Protein Markers of Biologic Treatment Response in Crohn's Disease
Icahn School of Medicine at Mount Sinai
FY2024$121,680R03DK132440 - Assessing Predictors of Response to Anti-Tumor Necrosis Alpha Therapy in Early Crohns Disease
Icahn School of Medicine at Mount Sinai
FY2023$189,342K23DK111995 - Blood Protein Markers of Biologic Treatment Response in Crohn's Disease
Icahn School of Medicine at Mount Sinai
FY2023$126,750R03DK132440
Awards in the NIH RePORTER records where a principal investigator name matches this physician at an organization in their practice state. Latest award years shown; each row links to the project record on RePORTER.
Similar KOLs
Other experts from the same institution or the same specialty.
Josep M. Llovet
Institució Catalana de Recerca i Estudis Avançats
Joseph J.�Y. Sung
Nanyang Technological University
Neeraj Bhala
The Royal Melbourne Hospital
Jordi Bruix
Hospital Clínic de Barcelona
A basic profile from our physician directory: identity and practice contact from the federal NPPES registry, research from OpenAlex, trials from ClinicalTrials.gov, payments from CMS Open Payments — shown itemized where we have matched records, as a count where we only have a total. This person hasn't been through our full identity-adjudication pipeline yet, so funding, congress activity and public presence aren't shown. Absence of a section means “not yet looked,” never “none found.”